Hostname: page-component-745bb68f8f-l4dxg Total loading time: 0 Render date: 2025-01-07T17:57:10.701Z Has data issue: false hasContentIssue false
  • English
  • Français

Tardive dyskinesia: natural history studies assist the pursuit of preventive therapies1

Published online by Cambridge University Press:  09 July 2009

Stephen M. Stahl
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Editorial
Information
Psychological Medicine , Volume 16 , Issue 3 , August 1986 , pp. 491 - 494
Copyright
Copyright © Cambridge University Press 1986

References

Barnes, T. R. E. & Braude, W. M. (1985). Akathisia variants and tardive dyskinesia. Archives of General Psychiatry 42, 874–878.Google Scholar
Burke, R. E., Fahn, S., Jankovec, J., Marsden, C. D., Lang, A. E., Gollomp, S. & Ilson, J. (1982). Tardive dystonia: late onset and persistent dystonia caused by antipsychotic drugs. Neurology 32, 1335–1346.CrossRefGoogle ScholarPubMed
Chouinard, G. (1982). Neuroleptic-induced supersensitivity psychosis. In Tardive Dyskinesia and Related Involuntary Movement Disorders (ed. DeVeaugh-Geiss, J.), pp. 109–115. John Wright: Boston.Google Scholar
Chouinard, G., Jones, B. D. & Annable, L. (1978). Neuroleptic-induced supersensitivity psychosis. American Journal of Psychiatry 135, 1409–1410.Google ScholarPubMed
Crow, T. J. (1981). Positive and negative schizophrenia symptoms and the role of dopamine. British Journal of Psychiatry 139, 251–254.CrossRefGoogle ScholarPubMed
Davidson, A. B., Boff, I., MacNeil, D. A. & Cook, L. (1983). Pharmacological effects of RO22–1319: a new antipsychotic agent. Psychopharmacology 79, 32–39.CrossRefGoogle Scholar
DeVeaugh-Geiss, J. (1980). Tardive Tourette syndrome. Neurology 30, 562–563.CrossRefGoogle ScholarPubMed
DeVeaugh-Geiss, J. (ed.) (1982). Tardive Dyskinesia and Related Involuntary Movement Disorders. John Wright: Boston.Google Scholar
Ferris, R., Cooper, B., Harfenist, M. & Maxwell, R. (1984). The pharmacology of new non-dopamine blocking antipsychotic, BW234U. Clinical Neuropharmacology 7, 146–147.Google Scholar
Fog, R. & Pakkenberg, H. (1980). Theoretical and clinical aspects of Tourette Syndrome (chronic multiple tics). Journal of Neural Transmission (Suppl.) 16, 211–215.Google Scholar
Forrest, D. V. (1979). Tardive dysphrenia and subjective akathisia. Journal of Clinical Psychiatry 40, 87.Google Scholar
Hokfelt, T., Fuxe, K. & Pernow, B. (eds.) (1986). Coexistence of Neuronal Messengers: A New Principle in Chemical Transmission. Progress in Brain Research. Elsevier: Amsterdam (in the press).Google Scholar
Iversen, L. L. (1983). Neuropeptides – what next? Trends in Neurosciences 6, 293–294.Google Scholar
Iversen, L. L. (1986). Chemicals signalling in the nervous system. In Coexistence of Neuronal Messengers: A New Principle in Chemical Transmission (ed. Hokfelt, T., Fuxe, K. and Pernow, B.). Progress in Brain Research. Elsevier: Amsterdam (in the press).Google Scholar
Jalfre, M., Bucher, B., Dorme, N., Mocquet, G. & Porsolt, R. D. (1983). Neuropharmacological profile of MD 790501, a new benzamide derivative. Archives Internationales de Pharmacodynamie et de Thérapie 264, 232–256.Google Scholar
Jeste, D. V. & Wyatt, R. P. (1979). In search of treatment for tardive dyskinesia: review of the literature. Schizophrenia Bulletin 5, 251–293.CrossRefGoogle ScholarPubMed
Klawans, H. L., Falk, D. K., Nausieda, P. A. & Weiner, W. J. (1978). Gilles de la Tourette Syndrome after long-term chlorpromazine therapy. Neurology 28, 1064–1066.CrossRefGoogle ScholarPubMed
Lundberg, J. M. & Hokfelt, T. (1983). Coexistence of peptides and classical neurotransmitters. Trends in Neurosciences 6, 325–333.CrossRefGoogle Scholar
Marsden, C. D., Tarsy, D. & Baldessarini, R. J. (1975). Spontaneous and drug-induced movement disorders in psychotic patients. In Psychiatric Aspects of Neurological Disease (ed. Benson, D. F. and Blumer, D.), pp. 219–265. Grune and Stratton: New York.Google Scholar
Nemeroff, C. B. & Cain, S. T. (1985). Neurotensin–dopamine interactions in the CNS. Trends in Pharmacological Sciences 4, 201–205.Google Scholar
Snyder, S. H. (1980). Brain peptides as neurotransmitters. Science 209, 976–983.Google Scholar
Stahl, S. M. (1980). Tardive Tourette syndrome in an autistic patient after long-term neuroleptic administration. American Journal of Psychiatry 137, 1267–1269.Google Scholar
Stahl, S. M. (1985). Akathisia and tardive dyskinesia: changing concepts. Archives of General Psychiatry 42, 915–917.Google Scholar
Stahl, S. M. (1986). Neuropharmacology of movement disorders: comparison of drug-induced and spontaneous movement disorders. In Movement Disorders (ed. Shah, N. S. and Donald, A. G.). Plenum: New York (in the press).Google Scholar
Stahl, S. M., Davis, K. L. & Berger, P. A. (1982). Neuropharmacology of tardive dyskinesia, spontaneous dyskinesia, and other dystonias. Journal of Clinical Psychopharmacology 2, 321–328.Google Scholar
Stahl, S. M., Thornton, J. E., Simpson, M. L., Berger, P. A. & Napoliello, M. J. (1985). GAMMA-Vinyl-GABA treatment of tardive dyskinesia and other movement disorders. Biological Psychiatry 20, 888–893.Google Scholar
Wilson, I. C., Garbutt, J. C., Lanier, C. F., Moylan, J., Nelson, W. & Prange, A. J. (1983). Is there a tardive dysmentia? Schizophrenia Bulletin 9, 187–192.Google Scholar